Saltar al contenido

United Therapeutics Corp (UTHR) stock: revenue, earnings & dividend

United Therapeutics Corp (UTHR, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener UTHR · Nasdaq Pharma & Biotech US-MD

Key figures

Fiscal year
2025
Revenue
3.18 bn $
Revenue growth
10.6 %
Revenue growth 5y (p.a.)
16.5 %
Net income
1.33 bn $
Net margin
41.9 %
Operating margin
46.9 %
Earnings per share (diluted)
27.86 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
7.88 bn $
Equity
7.1 bn $
Equity ratio
90.1 %
Return on equity
18.8 %
Cash
1.56 bn $
Operating cash flow
1.56 bn $
Free cash flow
1.04 bn $
Shares outstanding
42,588,726

History

Revenue by fiscal year

2016 1.6 bn $
2017 1.73 bn $
2018 1.63 bn $
2019 1.45 bn $
2020 1.48 bn $
2021 1.69 bn $
2022 1.94 bn $
2023 2.33 bn $
2024 2.88 bn $
2025 3.18 bn $

Net income by fiscal year

2021 476 m $
2022 727 m $
2023 985 m $
2024 1.2 bn $
2025 1.33 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20253.18 bn $1.33 bn $27.86 $–1.56 bn $
20242.88 bn $1.2 bn $24.64 $–1.33 bn $
20232.33 bn $985 m $19.81 $–978 m $
20221.94 bn $727 m $15.00 $–803 m $
20211.69 bn $476 m $10.06 $–598 m $
20201.48 bn $–11.54 $–756 m $
20191.45 bn $–-2.39 $–-206.6 m $
20181.63 bn $–13.39 $–778 m $
20171.73 bn $–9.31 $–474 m $
20161.6 bn $–15.25 $–644 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)